Roche wins CE mark for Alzheimer’s blood test that could transform early diagnosis

The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline

Eli Lilly launches Lormalzi for early Alzheimer’s treatment in India

Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence

C2N Diagnostics expands Alzheimer’s blood test to South Korea via BeauBrain partnership

Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test

Mahajan Imaging & Labs launches AI-driven blood test to detect Alzheimer’s early

Over 8.8?million Indians aged 60 and above currently live with dementia,

Merck unveils first human data for Alzheimer’s candidates

The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration

Novo Nordisk’s Semaglutide fails to slow Alzheimer’s progression in Phase 3 trials

The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years

Roche’s Elecsys pTau181 becomes first FDA-cleared blood test to rule out Alzheimer’s pathology in primary care

New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency

Leqembi wins NMPA nod for once-monthly IV dosing in early Alzheimer’s patients

LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment

European Commission approves Lilly’s Kisunla for treatment of early Alzheimer’s patients

Galimedix completes phase 1 study with oral small molecule GAL-101

The study further confirmed that GAL-101 effectively crosses the blood-brain barrier